Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease.

Mielke MM, Haughey NJ, Bandaru VV, Zetterberg H, Blennow K, Andreasson U, Johnson SC, Gleason CE, Blazel HM, Puglielli L, Sager MA, Asthana S, Carlsson CM.

Neurobiol Aging. 2014 May 27. pii: S0197-4580(14)00382-0. doi: 10.1016/j.neurobiolaging.2014.05.019. [Epub ahead of print]

PMID:
24952994
[PubMed - as supplied by publisher]
2.

The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.

Osorio RS, Ayappa I, Mantua J, Gumb T, Varga A, Mooney AM, Burschtin OE, Taxin Z, During E, Spector N, Biagioni M, Pirraglia E, Lau H, Zetterberg H, Blennow K, Lu SE, Mosconi L, Glodzik L, Rapoport DM, de Leon MJ.

Neurobiol Aging. 2014 Jun;35(6):1318-24. doi: 10.1016/j.neurobiolaging.2013.12.030. Epub 2013 Dec 27.

PMID:
24439479
[PubMed - in process]
3.

Amyloid-β metabolism in Niemann-Pick C disease models and patients.

Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Månsson JE, Blomqvist M, Gobom J, Andreasson U, Brinkmalm G, Vite C, Hecimovic S, Hastings C, Blennow K, Zetterberg H, Portelius E.

Metab Brain Dis. 2012 Dec;27(4):573-85. doi: 10.1007/s11011-012-9332-8. Epub 2012 Sep 1.

PMID:
22935999
[PubMed - indexed for MEDLINE]
4.

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH.

JAMA Neurol. 2013 May;70(5):594-9. doi: 10.1001/jamaneurol.2013.48.

PMID:
23479202
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures.

Shahim P, Rejdak R, Ksiazek P, Blennow K, Zetterberg H, Mattsson N, Rejdak K.

Eur J Neurol. 2014 Mar;21(3):486-91. doi: 10.1111/ene.12336. Epub 2013 Dec 26.

PMID:
24372994
[PubMed - in process]
6.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062. Epub 2013 Apr 9.

PMID:
23576130
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.

Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T.

Cerebrospinal Fluid Res. 2010 Jul 30;7:10. doi: 10.1186/1743-8454-7-10.

PMID:
20673341
[PubMed]
Free PMC Article
8.

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.

Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.

Brain. 2007 Sep;130(Pt 9):2320-6. Epub 2007 Jun 22.

PMID:
17586559
[PubMed - indexed for MEDLINE]
Free Article
9.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

PMID:
20932310
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.

Musiek ES, Holtzman DM.

Curr Opin Neurol. 2012 Dec;25(6):715-20. doi: 10.1097/WCO.0b013e32835a30f4. Review.

PMID:
23041958
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

Toledo JB, Xie SX, Trojanowski JQ, Shaw LM.

Acta Neuropathol. 2013 Nov;126(5):659-70. doi: 10.1007/s00401-013-1151-4. Epub 2013 Jun 29.

PMID:
23812320
[PubMed - indexed for MEDLINE]
12.

Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease.

Soldan A, Pettigrew C, Li S, Wang MC, Moghekar A, Selnes OA, Albert M, O'Brien R; BIOCARD Research Team.

Neurobiol Aging. 2013 Dec;34(12):2827-34. doi: 10.1016/j.neurobiolaging.2013.06.017. Epub 2013 Aug 1.

PMID:
23916061
[PubMed - indexed for MEDLINE]
13.

BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.

Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.

J Alzheimers Dis. 2010;20(1):253-60. doi: 10.3233/JAD-2010-1367.

PMID:
20164582
[PubMed - indexed for MEDLINE]
14.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
[PubMed - indexed for MEDLINE]
15.

Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology.

Tekirian TL.

J Alzheimers Dis. 2001 Apr;3(2):241-248.

PMID:
12214065
[PubMed - as supplied by publisher]
16.

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.

Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.

PMID:
16488378
[PubMed - indexed for MEDLINE]
17.

Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations.

Fortea J, Lladó A, Bosch B, Antonell A, Oliva R, Molinuevo JL, Sánchez-Valle R.

Neurodegener Dis. 2011;8(4):202-7. doi: 10.1159/000322229. Epub 2011 Jan 5.

PMID:
21212633
[PubMed - indexed for MEDLINE]
18.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
19.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10.

PMID:
22473769
[PubMed - indexed for MEDLINE]
20.

Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.

Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2009;28(1):88-94. doi: 10.1159/000233353. Epub 2009 Aug 12.

PMID:
19672066
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk